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Abstract 
Background: There is an urgent need for new antimicrobial compounds to treat various lung infections caused by 
multidrug-resistant Pseudomonas aeruginosa (MDR-PA).
Methods: We studied the potency of Mul-1867 against MDR-PA isolates from patients with cystic fibrosis, chronic 
obstructive pulmonary disease, and ventilator-associated pneumonia. The minimal inhibitory concentrations (MICs) 
and minimum biofilm eliminating concentrations (MBECs), defined as the concentrations of drug that kill 50 % 
(MBEC50), 90 % (MBEC90), and 100 % (MBEC100) of the bacteria in preformed biofilms, were determined by using the 
broth macrodilution method.
Results: Mul-1867 exhibited significant activity against MDR-PA and susceptible control strains, with MICs ranging 
from 1.0 to 8.0 µg/mL. Mul-1867 also possesses anti-biofilm activity against mucoid and non-mucoid 24-h-old MDR-
PA biofilms. The MBEC50 value was equal to onefold the MIC. The MBEC90 value ranged from two to fourfold the MIC. 
Moreover, Mul-1867 completely eradicated mature biofilms at the concentrations tested, with MBEC100 values ranging 
between 16- and 32-fold the MIC. Mul-1867 was non-toxic to Madin-Darby canine kidney (MDCK) cells at concentra-
tions up to 256 µg/mL.
Conclusion: Overall, these data indicate that Mul-1867 is a promising locally acting antimicrobial for the treatment 
and prevention of P. aeruginosa infections.
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Background
Pseudomonas aeruginosa is an important pathogen con-
tributing to lung infections in patients with pulmonary 
diseases such as cystic fibrosis (CF), chronic obstructive 
pulmonary disease (COPD), and ventilator-associated 
pneumonia (VAP) [1–3]. By 21  years of age, most CF 
patients are chronically infected with P. aeruginosa that, 
once established, is difficult to eradicate and is associ-
ated with major morbidity [4–6]. P. aeruginosa is also an 
important contributor to acute exacerbations in COPD 
and VAP [7]. Some P. aeruginosa strains are mucoid due 
to overexpression of alginate, and are less susceptible to 
the host immune system [8]. Overproduction of alginate, 
and conversion of P. aeruginosa to a mucoid phenotype, 
are considered markers of chronic lung infections and 
indicate a decreased life expectancy and a more rapid 
decline in pulmonary function [9].
Both mucoid and non-mucoid strains of P. aeruginosa 
form biofilms that are associated with persistence in 
chronic infections, and also contribute to bacterial col-
onization in acute infections [10]. Established biofilms 
display high resistance to antimicrobials, and finding 
ways to disrupt these films is a critical goal in combat-
ting these infections [11, 12]. P. aeruginosa survival in 
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biofilms may be determined by multiple factors includ-
ing the surface film and the presence of extracellular 
polymeric substances [13, 14]. Moreover, clinical iso-
lates of multidrug resistant P. aeruginosa (MDR-PA) are 
being observed with increasing frequency [15]. Thus, 
biofilms formed by MDR-PA are a serious and often 
fatal problem for patients with lung infections, and 
many antibiotics are ineffective against bacteria in bio-
film communities at concentrations of 10–1000 times 
the expected minimum inhibitory concentration (MIC) 
[16].
During the last decade, it became evident that exist-
ing antibiotics were unable to treat respiratory infections 
caused by P. aeruginosa effectively [17]. Lung infections 
caused by MDR-PA were poorly responsive even to nebu-
lized therapy when the aerosolized antibiotics achieved 
high concentrations directly at the pathological site [18]. 
It was also shown that many antibiotics, even when able 
to decrease the number of live bacteria within the bio-
film, could not completely eradicate preformed biofilms 
[19].
The poor therapeutic results with existing antibiot-
ics revealed a critical need for the development of new 
antimicrobials active against MDR-PA that can be used 
to treat lung infections. The goal of this study was to 
examine in  vitro MICs and minimal biofilm eradica-
tion concentrations (MBECs) of the novel antimicrobial 
compound, Mul-1867 (poly-N,N’-hexamethyleneguani-
dine-poly-N1,N4-hexamethyleneaminoguanidine; Fig. 1). 
The mechanism of action of Mul-1867 involves a non-
specific attack on the cell walls of MDR-PA isolated from 
patients with respiratory tract infections [20]. Further-
more, the anti-biofilm efficacy of Mul-1867 against pre-




Mul-1867 (Fig. 1) was synthesized by TGV-Therapeutics 
(New York, NY, USA).
The antibiotics used for these studies included amika-
cin, aztreonam, ceftazidime, meropenem, piperacillin, 
and tobramycin, which are currently administered to 
treat lung infections in patients with CF, COPD, or VAP. 
These antibiotics were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
Bacterial strains and growth conditions
MDR-PA isolates from CF patients including the AGR14, 
MR45, and VT-CF-234 strains, as well as one susceptible 
isolate, SEV 7; were obtained from the CF Foundation 
Therapeutics Development Network Resource Center for 
Microbiology at Seattle Children’s Hospital (Seattle, WA, 
USA) and from the Institute of Human Microbiology, 
LLC (DE, USA). MDR-PA isolates from COPD and VAP 
patients, VT-COPD-274 and VT-VAP-72, respectively, 
were supplied by the Institute of Human Microbiology. 
The three strains classified phenotypically as mucoid 
were SEV 7, VT-CF-234, and VT-COPD-274. The strain 
used for quality control of the antibiotic panels was P. 
aeruginosa ATCC 27853 from the American Type Cul-
ture Collection (Manassas, VA, USA).
All bacterial strains were subcultured from freezer 
stocks onto Mueller–Hinton agar plates (Oxoid Ltd., 
London, England) and incubated at 37  °C overnight. All 
subsequent liquid subcultures were derived from colonies 
isolated from these plates and were grown in Mueller–
Hinton broth (MHB) (Oxoid). The isolates were catego-
rized as susceptible, intermediate, or resistant according 
to the Clinical and Laboratory Standards Institute (CLSI) 




























































Fig. 1 Chemical structure of Mul-1867 n = 1–20
Page 3 of 6Tetz et al. Ann Clin Microbiol Antimicrob  (2016) 15:19 
In vitro antimicrobial susceptibility testing
The MICs for antimicrobials were determined by the 
broth macrodilution method according to CLSI guide-
line [22, 23]. A standard bacterial inoculum of 5 ×  105 
colony forming units (CFU)/mL was used. Serial twofold 
dilutions of the antimicrobials were prepared in cation-
adjusted MHB. The MIC was defined as the lowest con-
centration of antibiotic that completely inhibited visible 
growth. Experiments were conducted in triplicate.
Effect of Mul‑1867 against P. aeruginosa biofilms
In each well of a 96-well flat-bottom polystyrene tissue 
culture microtiter plate (Sarstedt, Numbrecht, Germany), 
200 μL of a standardized P. aeruginosa inoculum (5 × 105 
CFU/mL) in cation-adjusted MHB were added. Follow-
ing a 24  h incubation period at 37  °C, biofilm samples 
were washed twice with phosphate-buffered saline to 
remove non-adherent bacteria and then exposed for 24 h 
to 200 μL of MHB containing Mul-1867 at 1-, 2-, 4-, 8-, 
16-, 32-, and 64-fold the MIC. Untreated biofilms were 
used as the negative controls. After the exposure, well 
contents were aspirated to prevent antimicrobial car-
ryover and each well was washed three times with sterile 
deionized water.
To estimate the CFU number, biofilms were scraped 
thoroughly, with particular attention paid to the well 
edges [11]. The well contents were aspirated, placed in 
1 mL of isotonic phosphate buffer (0.15 M, pH 7.2), and 
the total CFU number was determined by serial dilution 
and plating on Mueller-Hinton agar.
The MBECs were determined as the concentrations 
of drug that killed 50 % (MBEC50), 90 % (MBEC90), and 
100  % (MBEC100) of the bacteria in preformed biofilms 
compared to the untreated control (100  % viability). 
MBEC sensitivities were determined using the 2012 Clin-
ical and Laboratory Standards Institute guidelines for 
interpretation [23]. Tests were performed in triplicate on 
three separate occasions, and the results were averaged.
Cytotoxicity assay
Cytotoxicity of Mul-1867 on Madin-Darby canine kidney 
(MDCK) cells was determined by the microculture tetra-
zolium (MTT) assay. Briefly, cells (1  ×  105/well) were 
plated in 100 μL of minimal essential media in 96-well 
plates and incubated overnight in a 5 % CO2 atmosphere. 
Serial dilutions of Mul-1867, with final concentrations 
corresponding to a range of 8–256  µg/mL, were added 
to the cells that were then incubated at 37  °C for a fur-
ther 24  h. Control wells were treated with sterile water. 
MTT analysis was then performed based on the standard 
method [24].
After incubation, an aliquot of [3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] solution (Sigma-
Aldrich, St. Louis, MO, USA) at 0.5 mg/mL was added to 
each well, and following a further 30  min incubation at 
37 °C, the medium was discarded and the formazan blue 
formed in the cells was dissolved with 100 μL of dimethyl 
sulfoxide. Absorbance at 570 nm was determined with a 
microplate reader (Stat-Fax-2100, Awareness Technology 
Inc, USA). The absorbance of the formazan formed in 
non-treated cells was considered 100 % viability.
Statistical analyses
Results of the cytotoxicity assay are presented as 
mean ± standard deviation of three independent experi-
ments. All statistical analyses were performed using the 
statistics package Statistica for Windows (version 5.0). 
Results are reported as the mean  ±  standard error for 
each group. Non-parametric paired Wilcoxon signed 
rank test was applied to analyse pre- and post-challenge 
differences. P < 0.05 was considered significant.
Results
In vitro antimicrobial susceptibility testing of P. aeruginosa 
isolates
The MICs of Mul-1867 and other antibiotics against non-
mucoid P. aeruginosa isolates are shown in Table 1.
Table 1 Bactericidal activities of Mul-1867 and other antibacterials against non-mucoid P. aeruginosa isolates
a ND no data
Antibacterials Susceptibility  
breakpoint (µg/mL)
P. aeruginosa strain minimal inhibitory concentration (µg/mL)
AGR14 MR 45 VT‑VAP‑72 ATCC 27853
Mul-1867 NDa 8 8 4 1
Amikacin ≤16 128 256 128 4
Aztreonam ≤8 32 128 64 2
Ceftazidime ≤8 32 32 16 2
Meropenem ≤2 32 64 32 1
Piperacillin ≤16 >256 256 128 4
Tobramycin ≤4 32 32 32 1
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Mul-1867 exhibited significant activity against all iso-
lates that were resistant to amikacin, aztreonam, cef-
tazidime, meropenem, piperacillin, and tobramycin 
according to CLSI criteria, as well as against susceptible 
and control strains.
Of the seven MDR-PA isolates, three had the mucoid 
phenotype that is widespread among CF patients and is 
associated with reduced success of treatment. Mul-1867 
exhibited a high level of antimicrobial activity against 
mucoid MDR-PA strains irrespective of their resistance 
to other antibiotics (Table 2) [25, 26].
There was no statistically significant difference between 
the activity of Mul-1867 against the mucoid vs. non-
mucoid P. aeruginosa strains. The MIC values ranged 
from 1 to 8 µg/mL for the non-mucoid strains, and from 
2 to 4 µg/mL for the mucoid strains.
Effect of Mul‑1867 against preformed P. aeruginosa 
biofilms
The anti-biofilm activity of Mul-1867 against 24-h-old P. 
aeruginosa biofilms was analyzed to reveal possible dif-
ferences in susceptibility patterns between non-mucoid 
and mucoid P. aeruginosa strains. The activity of Mul-
1867 on mature biofilms, tested at concentrations equal 
to a multiple of the MIC, is summarized in Table 3. After 
24 h of growth, the CFUs of P. aeruginosa AGR14 and P. 
aeruginosa VT-CF-234 biofilms were 1.8 × 108 CFU/mL 
and 3.5 × 108 CFU/mL, respectively.
A comparison between the MIC and MBEC values 
indicated that Mul-1867 was a highly active antimicro-
bial exhibiting dose-dependent effects against the P. 
aeruginosa strains tested. Mul-1867 showed MBEC50 
and MBEC90 values of 1- and 4-fold the MIC, respec-
tively, against a non-mucoid strain. Mul-1867 dis-
played comparable activity against a mucoid strain with 
MBEC50 and MBEC90 values of 1- and twofold the MIC, 
respectively.
Reduction in cell numbers by 90 % suggested that Mul-
1867 has the potential for biofilm eradication, which is 
an important goal in antimicrobial treatment. Thus, we 
determined the MBEC100 after treatment of P. aeruginosa 
biofilms with Mul-1867 for 24 h.
In this assay, Mul-1867 completely eradicated mature 
P. aeruginosa biofilms at the concentrations tested, with 
MBEC100 values of 32- and 16-fold the MIC for the 
AGR14 and VT-CF-234 strains, respectively. The ability 
to eradicate a biofilm at a concentration eightfold higher 
than that required to reduce biofilm bacteria by 90 % sug-
gested that Mul-1867 possesses significant anti-biofilm 
activity.
Cell cytotoxicity of Mul‑1867
The compound did not exhibit any statistically significant 
cytotoxicity against MDCK cells at concentrations rang-
ing from 8 to 256 µg/mL, as tested by the MTT assay 24 h 
after challenging with Mul-1867 (Fig. 2).
Discussion
P. aeruginosa presents substantial problems for patients 
with CF, and is a major predictor of morbidity [27]. For 
the last decade, the emergence of MDR-PA strains has 
posed treatment challenges in patients with COPD and 
VAP [28]. In the current study, we found that a novel 
Table 2 Minimal inhibitory concentrations of  Mul-1867 
and other antibacterials against mucoid P. aeruginosa iso-
lates




P. aeruginosa strain minimal 
inhibitory concentration (µg/ml)
SEV 7 VT‑CF‑234 VT‑COPD‑274
Mul-1867 NDa 2 2 4
Amikacin ≤16 128 64 256
Aztreonam ≤8 64 64 128
Ceftazidime ≤8 2 32 32
Piperacillin ≤16 2 64 128
Meropenem ≤2 32 8 16
Tobramycin ≤4 16 128 64
Table 3 Susceptibility results of  Mul-1867 against  P. aer-
uginosa strains
MBEC minimum biofilm eliminating concentrations








No 8 32 256
P. aeruginosa 
VT-CF-234



















Mul-1867 concentration µg/mL 
Fig. 2 Cytotoxic effect of Mul-1867 on Madin-Darby canine kidney 
cell lines as determined by the microculture tetrazolium assay
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drug candidate, Mul-1867, exhibits a high level of antimi-
crobial activity against both MDR and susceptible clinical 
isolates of P. aeruginosa from patients with life-threaten-
ing lung infections.
We showed previously that Mul-1867 is a fast-acting 
antimicrobial whose mechanism of action involves a 
nonspecific attack on the bacterial cell wall that causes 
leakage of cell contents [20]. Mucoid strains lead to the 
persistence of P. aeruginosa infections. The data avail-
able in the literature concerning the effect of mucoidity 
on antimicrobial susceptibility show some differences 
depending on the type of antibiotic being tested [29]. Our 
data indicate that there is no cross-resistance between 
amikacin, aztreonam, ceftazidime, meropenem, pipera-
cillin, and tobramycin vs. Mul-1867 against susceptible 
and MDR-PA strains tested in this study.
P. aeruginosa biofilms respond poorly to treatment with 
existing medicines due to the presence of additional bar-
riers including a surface film or extracellular polymeric 
substances that reduce antibiotic penetration [30]. Bio-
films formed by MDR-PA are almost completely insensi-
tive to treatment with antibiotics that have high MBEC 
values that cannot be achieved at the site of infection 
using currently recommended dosages, or even with local 
administration directly to the site of infection [31]. There 
are also reports that biofilms formed by some strains of P. 
aeruginosa cannot be eradicated at any concentration of 
antibiotics that are commonly used for therapy. Impor-
tantly, however, Mul-1867 was equally effective against 
mucoid and non-mucoid P. aeruginosa strains.
The MBEC90/MIC ratio is an important parameter 
for choosing the best antibacterial to treat P. aeruginosa 
biofilm-associated infections (lower is better). Our stud-
ies revealed that Mul-1867 possessed low MBEC90/MIC 
ratios (between two and four). Moreover, biofilms formed 
by both non-mucoid and mucoid P. aeruginosa strains 
were totally eradicated with Mul-1867 at concentrations 
of 32- and 16-fold the MIC, respectively.
Positively charged antibiotics bind to extracellular poly-
meric substance and extracellular DNA, which decreases 
their bioavailability [30]. Mul-1867 is a positively charged 
molecule, and its antimicrobial activity was also reduced 
by the biofilm’s components. However, its activity level 
remained high enough to achieve total eradication of 
biofilms.
Cell viability assessed by the MTT assay revealed that 
Mul-1867 did not display cytotoxic effects at the tested 
concentrations (between 8 to 256 µg/mL). The absence of 
apparent toxicity to MDCK cells at the highest concen-
tration of Mul-1867 that was used against the least sensi-
tive P. aeruginosa strain tested in this study (AGR14) is a 
notable attribute of this topical antimicrobial compound.
The high levels of Mul-1867 activity against the clini-
cal isolates tested in this study are consistent with those 
found in our previous work [20]. This demonstrates the 
broad antimicrobial activity of this molecule against 
planktonic and sessile gram-positive and gram-negative 
bacteria. The efficacy of Mul-1867 against both non-
mucoid and mucoid strains of P. aeruginosa raises the 
possibility that it may serve as a locally acting antimicro-
bial compound and may be able to successfully eradicate 
biofilm infections caused by P. aeruginosa.
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